عربي English Türkçe اردو فارسى
Logo
Latest News
Varieties

World Awaits Launch of Saudi Astronauts' Mission to ISS

Saudi astronauts Rayyanah Bernawi and Ali al-Qarni (SPA)
Saudi astronauts Rayyanah Bernawi and Ali al-Qarni (SPA)
TT
TT

World Awaits Launch of Saudi Astronauts' Mission to ISS

Saudi astronauts Rayyanah Bernawi and Ali al-Qarni (SPA)
Saudi astronauts Rayyanah Bernawi and Ali al-Qarni (SPA)

Saudi astronauts, Rayyanah Bernawi and Ali al-Qarni, completed their final preparations as part of the AX-2 crew for the launch of their mission at the International Space Station (ISS), which will be launched atop the Falcon 9 rocket and the Dragon spacecraft.

The historic flight is a turning point in the Saudi space sector, being part of Saudi Arabia's Astronauts Program, launched on September 22, 2022.

The Saudi astronauts will conduct 14 scientific and research experiments during their mission to the ISS, contributing to scientific research.

The new mission affirms Saudi Arabia's ambition to benefit from space in all fields, as it is a giant future sector with global visions of sustainability, technology, and scientific research.

Saudi Arabia achieved several developments in this sector to be among the new space leadership, adopting its emerging activities while providing the infrastructure needed to ensure the sector's empowerment and prosperity.

NASA had announced that Bernawi and Qarni would take off in Spring 2023 from the Kennedy Space Center in Florida on a SpaceX rocket towards the ISS, accompanied by John Schofner and Peggy Whitson.

The Saudi astronauts will conduct various experiments and studies during the space mission.

They will investigate changes in vital indicators in the blood that reflect functional brain tissues during short-term space missions and determine the safety of such trips for the brain.

Additionally, they will measure the effect of short-term space flights on telomere length and conduct a mydriasis experiment to measure intracranial pressure. Other investigations will focus on enhancing knowledge of spaceflight-associated neuro-ocular syndrome (SANS) by measuring electrical activity in the brain using EEG and studying the diameter of the optic nerve envelope for astronauts.

The mission will also explore cerebral perfusion and postural adjustments of the brain in microgravity using near-infrared spectroscopy as a non-invasive technique.

The official logo of the Kingdom's scientific mission to the ISS is a circular shape featuring the Saudi flag and says "Saudi Arabia towards space" alongside the names of the two Saudi astronauts.

The logo embodies the noble goals of the Kingdom's scientific mission, centered around empowering people, protecting the planet, and opening new horizons through the research the astronauts will conduct in health and environmental sustainability.

The logo will be placed on the official uniform of the crew, as it is customary for all space flights to have an official logo for each mission before the team leaves the planet Earth into space.

Earlier this month, Crown Prince Mohammed bin Salman received Bernawi, al-Qarni, Mariam Fardous, and Ali al-Ghamdi, before the launch of the Kingdom's scientific mission to the International Space Station.

The Crown Prince welcomed the crew, reiterating the importance of the space sector as a significant pillar in enhancing the Kingdom's global competitiveness, emphasizing at the same time the significance of space exploration in serving science and humanity.

He also noted that the Saudi people are pinning great hopes on Bernawi and Qarni as ambassadors and representatives of the Kingdom at the ISS in a mission with noble objectives to empower humanity, protect the planet and open new horizons for research in health and a sustainable environment.

The space sector represents an economic force and includes developing and providing space products and services to end users. It also constitutes a long chain of added values from research and development through space equipment manufacturers to providers of space products and services.

According to the 2018 Stanley Morgan report, the size of the space industry in the world is valued at over $350 billion, while it is expected to generate $ 1.1 trillion in 2040 and about $2.7 trillion by 2050.

Most Viewed

 
 
Varieties

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
TT
TT

Blood Tests Allow 30-year Estimates of Women's Cardio Risks, New Study Says

A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights
A woman jogs in a park in Saint-Sebastien-sur-Loire near Nantes, France January 19, 2024. REUTERS/Stephane Mahe/File Photo Purchase Licensing Rights

Women’s heart disease risks and their need to start taking preventive medications should be evaluated when they are in their 30s rather than well after menopause as is now the practice, said researchers who published a study on Saturday.

Presenting the findings at the European Society of Cardiology annual meeting in London, they said the study showed for the first time that simple blood tests make it possible to estimate a woman’s risk of cardiovascular disease over the next three decades.

"This is good for patients first and foremost, but it is also important information for (manufacturers of) cholesterol lowering drugs, anti-inflammatory drugs, and lipoprotein(a)lowering drugs - the implications for therapy are broad," said study leader Dr. Paul Ridker of Brigham and Women’s Hospital in Boston, Reuters reported.

Current guidelines “suggest to physicians that women should generally not be considered for preventive therapies until their 60s and 70s. These new data... clearly demonstrate that our guidelines need to change,” Ridker said. “We must move beyond discussions of 5 or 10 year risk."

The 27,939 participants in the long-term Women’s Health Initiative study had blood tests between 1992 and 1995 for low density lipoprotein cholesterol (LDL-C or “bad cholesterol”), which are already a part of routine care.

They also had tests for high-sensitivity C-reactive protein (hsCRP) - a marker of blood vessel inflammation - and lipoprotein(a), a genetically determined type of fat.

Compared to risks in women with the lowest levels of each marker, risks for major cardiovascular events like heart attacks or strokes over the next 30 years were 36% higher in women with the highest levels of LDL-C, 70% higher in women with the highest levels of hsCRP, and 33% higher in those with the highest levels of lipoprotein(a).

Women in whom all three markers were in the highest range were 2.6 times more likely to have a major cardiovascular event and 3.7 times more likely to have a stroke over the next three decades, according to a report of the study in The New England Journal of Medicine published to coincide with the presentation at the meeting.

“The three biomarkers are fully independent of each other and tell us about different biologic issues each individual woman faces,” Ridker said.

“The therapies we might use in response to an elevation in each biomarker are markedly different, and physicians can now specifically target the individual person’s biologic problem.”

While drugs that lower LDL-C and hsCRP are widely available - including statins and certain pills for high blood pressure and heart failure - drugs that reduce lipoprotein(a) levels are still in development by companies, including Novartis , Amgen , Eli Lilly and London-based Silence Therapeutics.

In some cases, lifestyle changes such as exercising and quitting smoking can be helpful.

Most of the women in the study were white Americans, but the findings would likely “have even greater impact among Black and Hispanic women for whom there is even a higher prevalence of undetected and untreated inflammation,” Ridker said.

“This is a global problem,” he added. “We need universal screening for hsCRP ... and for lipoprotein(a), just as we already have universal screening for cholesterol.”